Frankfurt
11.11.26 | 08:45
0,544 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | AlzeCure Pharma: AlzeCure publishes its interim report for January - September 2026 | 382 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / November 11, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6) today announced that its interim report for the period January - September 2026 is now available... ► Artikel lesen | |
| 27.10. | AlzeCure Pharma Announces Change of CEO Ahead of Next Phase of Development | 532 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / October 27, 2026 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (FN STO:ALZCUR), which develops small-molecule drug candidates for CNS diseases with a... ► Artikel lesen | |
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| 08.10. | AlzeCure Pharma to Present at Aktiespararna in Stockholm on 14 October | 324 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / October 8, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease... ► Artikel lesen | |
| 22.09. | AlzeCure Pharma to Present at Swiss Nordic Bio 2026 in Zurich | 367 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / September 22, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease... ► Artikel lesen | |
| 18.09. | AlzeCure Pharma Publishes Updated Company Presentation Following the Eli Lilly and QuantumCell Agreements | 522 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / September 18, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus... ► Artikel lesen | |
| 08.09. | AlzeCure Pharma to Present at Aktiedagen in Stockholm on September 15 | 409 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / September 8, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus... ► Artikel lesen | |
| 27.08. | AlzeCure Pharma to Present at The Pareto Securities 17th Annual Healthcare Conference on September 2 | 571 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 27, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus... ► Artikel lesen | |
| 26.08. | AlzeCure Pharma AB: AlzeCure publishes its interim report for January - June 2026 | 235 | GlobeNewswire (Europe) | AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - June 2026 is now available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/
"During... ► Artikel lesen | |
| 18.08. | AlzeCure Pharma: AlzeCure Receives a USD 10 Million Upfront Payment and Completes Initial Transaction with Lilly | 1.650 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 18, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company")(STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus... ► Artikel lesen | |
| 12.08. | AlzeCure Pharma: AlzeCure Receives a Total Upfront Payment of USD 12 million and Completes the Initial Transaction with QuantumCell | 645 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 12, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus... ► Artikel lesen | |
| 03.08. | AlzeCure Pharma Resolves on a Directed Share Issue to QuantumCell | 437 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 3, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6) ("AlzeCure" or the "Company") announced in a press release on 1 July 2026 that the Company had entered... ► Artikel lesen | |
| 02.07. | AlzeCure Pharma: Final Outcome of AlzeCure's Rights Issue | 675 | ACCESS Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO RUSSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES... ► Artikel lesen | |
| 01.07. | QuantumCell commits $2.2bn on AlzeCure's Alzheimer's platform | 3 | Pharmaceutical Technology | ||
| 01.07. | Backed by top-tier VCs, stealthy biotech bags AlzeCure Alzheimer's asset in $2.2B deal | 4 | FierceBiotech | ||
| 01.07. | AlzeCure Pharma Aktie schießt nach milliardenschwerem Lizenzdeal in die Höhe | 5 | Investing.com Deutsch | ||
| 01.07. | AlzeCure-Aktie: Milliarden-Deal treibt Kurs auf Hoch seit 2022 | 1 | Investing.com Deutsch | ||
| 01.07. | AlzeCure Pharma Enters an Out-Licensing and Collaboration Agreement with QuantumCell ApS for the NeuroRestore ACD856 Project | 804 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 1, 2026 / AlzeCure Pharma AB (publ) ("AlzeCure")(STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's... ► Artikel lesen | |
| 29.06. | Communique from the Annual General Meeting of AlzeCure Pharma on 29 June 2026 | 737 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 29, 2026 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - Today, 29 June 2026, the annual general meeting was held in AlzeCure Pharma AB (publ) (the "Company"). Below... ► Artikel lesen | |
| 16.06. | AlzeCure Pharma AB: Positive results from the Phase Ib clinical study of NeuroRestore ACD856, under development for Alzheimer's | 681 | GlobeNewswire (Europe) | AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that... ► Artikel lesen | |
| 16.06. | AlzeCure Pharma AB: The subscription period in AlzeCure Pharma's Rights Issue begins today | 549 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE PUBLISHED, RELEASED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO RUSSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH... ► Artikel lesen |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 487,95 | -0,58 % | 99 Millionen Dollar mit neuer Gentherapie: Vertex und CRISPR Therapeutics legen zu - Mesoblast wächst um 44 Prozent | ||
| VIATRIS | 18,422 | -1,39 % | Viatris Inc. Q3 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for Viatris Inc. (VTRS):Earnings: -$325.3 million in Q3 vs. -$128.2 million in the same period last year.
EPS: -$0.28 in Q3 vs. -$0.11... ► Artikel lesen | |
| ALTIMMUNE | 1,750 | +0,92 % | Altimmune, Inc: Altimmune Announces Third Quarter 2026 Financial Results and Business Update | ||
| SELLAS LIFE SCIENCES | 7,480 | -0,27 % | Sellas Life Sciences Group: Regal-Studie erreicht die nächste Marke, aber die Aktie fällt - vor der Schlussanalyse | ||
| OPKO HEALTH | 1,550 | +0,65 % | Opko sees FY 2026 continuing-ops revenue of $268M-$278M following $722M LabCorp asset sale agreement | ||
| JAGUAR HEALTH | 0,437 | +0,07 % | Jaguar Health, Inc.: Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders | SAN FRANCISCO, CA / ACCESS Newswire / November 6, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's November 6, 2026 Special Meeting... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 14,600 | +0,55 % | Alliance Advisors LLC: Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences | Little Falls, New Jersey--(Newsfile Corp. - May 19, 2026) - Alliance Advisors is pleased to congratulate Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) on the successful completion of its tender offer... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 1,380 | 0,00 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update | San Diego, California--(Newsfile Corp. - November 12, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today reported financial results for the third quarter ended September... ► Artikel lesen | |
| LIPOCINE | 1,610 | 0,00 % | Lipocine Inc.: Lipocine Doses First Participant in BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression | LPCN 1154 is being developed as a 48-hour oral treatment intended for at-home use in postpartum depressionApproximately 120 participants planned for the study, which incorporates insights from the previous... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 3,814 | +2,47 % | Aclaris Therapeutics, Inc. - 8-K, Current Report | ||
| PHOTOCURE | 3,980 | +3,78 % | Photocure Provides Update on AssureMDx and Anticipated Medicare Coverage Timeline | Photocure Provides Update on AssureMDx and Anticipated Medicare Coverage Timeline
OSLO, Norway, Nov. 9, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today provides... ► Artikel lesen | |
| EUROBIO SCIENTIFIC | 26,400 | +1,15 % | Eurobio Scientific: Results for the first semester of fiscal year 2026 | RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2026 Revenue up 4.5% to 84.5 M€ Proprietary products account for 37% of revenue46% of revenue generated outside France Free cash flow of €4 million after... ► Artikel lesen | |
| MEDICURE | 2,380 | -3,25 % | Medicure, Inc.: Medicure Announces Grant of Stock Options | WINNIPEG, MB / ACCESS Newswire / October 1, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals... ► Artikel lesen | |
| BAYER | 56,52 | -0,98 % | Wendepunkt bei Bayer!: Prognose rauf, Aktie springt hoch! Was jetzt kommen könnte! | © Foto: Bayer AGPlötzlich dreht sich der Wind bei Bayer. Jahrelang gab es für die Leverkusener vor allem Ärger, Klagen und rote Zahlen. Jetzt legt der Konzern ein Quartal vor, das selbst die Pessimisten... ► Artikel lesen | |
| MERCK KGAA | 151,15 | +1,21 % | Merck erhält US-Zulassung für Pimjetmi gegen seltene Gelenktumoren | Der Darmstädter Pharmakonzern Merck KGaA kann sein Krebsmedikament Pimjetmi (Pimicotinib) künftig auch in den USA vermarkten. Die Arzneimittelbehörde FDA hat den Wirkstoff zur Behandlung erwachsener... ► Artikel lesen |
ALZECURE PHARMA AB gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,544 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.